Central Cardiovascular Research Foundation
Central Cardiovascular
Research Foundation (CCRF) began conducting clinical research in March
of 1999. Since its inception, CCRF has participated in numerous
Phase II-IV clinical trials, including drug and device trials
evaluating therapies for the prevention and treatment of dyslipidemia,
hypertension, coronary artery disease, arrhythmias and heart failure,
but with particular emphasis on devices being investigated for use in
cardiac and vascular interventional procedures. CCRF participated
in three of the groundbreaking clinical trails evaluating carotid
stenting, as well as covered stents for saphenous vein grafts, cooling
as an adjunct to coronary intervention in acute myocardial infarction,
and drug-eluting stents among others.
The two primary goals of CCRF are to conduct clinical research with
excellence and integrity to benefit our patients while allowing the
opportunity to utilize innovative devices. We employ registered
nurses who are certified clinical research coordinators (CCRC).
This is the highest level of accreditation in research, assuring the
best provision of care to our patients and competence with regard to
the latest FDA guidelines. The second goal of CCRF is focused on the
provision of education to physicians and nurses on a broad range of
topics including *gloves-on* peripheral intervention proctorship
training programs for physicians, and lectures and training sessions
for doctors and nurses alike.
ONGOING RESEARCH STUDIES AT CENTRAL CARDIOVASCULAR INSTITUTE:
· SYMBIOT III: The purpose of this study
is to see how safe and effective the SYMBIOT III stent is in treating
coronary artery disease in the grafts from previous bypass
surgeries. The SYMBIOT III Covered Stent System is different from
other stents because it has a special material covering the stent which
is believed to reduce the chances of grafts re-blocking, and/or reduce
the chance of a heart attack.
ENROLLMENT COMPLETED (Boston Scientific)
· BEACH: This study is being done to
evaluate an investigational procedure called carotid artery stenting
for patients who are at high risk for complications from surgery, using
the Monorail Carotid Wallstent™ and the FilterWire EZ™
System.
ENROLLMENT COMPLETED (Boston Scientific)
· MAVErIC II: This study will evaluate
an investigational procedure called carotid artery stenting for
patients who are at high risk for complications from the standard
surgery, using the Medtronic AVE Self-Expanding Carotid Stent System
and the GuardWire® 3-6 Temporary Occlusion and Aspiration
System.
ENROLLMENT COMPLETED (Medtronic)
· SPIRIT III: The purpose of this study is to
evaluate the safety and effectiveness of a new drug delivering stent
system, the XIENCE™ V EECSS compared to the FDA approved
TAXUS® EXPRESS2™ PEC System, in treating the narrowing of
coronary arteries.
ENROLLMENT COMPLETED (Guidant)
· IMPROVE-IT: This study is being done to
compare two drugs, Vytorin® and Zocor®, and their effectiveness
to lower LDL-C (“bad cholesterol”). This will help to
know if having a lower LDL-C level makes it less likely that people
with coronary artery disease will develop unstable angina and heart
attacks.
ENROLLMENT ONGOING (Schering-Plough)
· PEGASUS CRT (Dr. Muse): This study
looks at three different programming levels for the CONTAK RENEWAL®
cardiac resynchronization therapy defibrillator (CRT-D). The
purpose of this study is to show how these modes may assist patients in
daily activities.
ENROLLMENT ONGOING (Guidant)
UPCOMING STUDY
· CAPTURE 2 (Dr. Wholey): This study is
being done to collect data about patients undergoing carotid artery
stenting with the already approved Guidant ACCULINK stent together with
the ACCUNET embolic protection device.
ENROLLMENT TO BEGIN October 2006 (Abbott)
If you are interested in obtaining more information or participating in one of the above listed studies then please call 210-212-8691.